How dietary fats affect growth and cell behavior in aggressive childhood midline brain tumors (H3K27M)
Mechanism and functional consequences of dietary lipids in lineage specification and tumor growth in oncohistone gliomas
This work looks at whether omega‑3 dietary fats can shift aggressive childhood midline brain tumor cells toward more mature cell types and slow their growth.
Quick facts
| Grant type | U01 cooperative agreement |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Dana-Farber Cancer Inst NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project ID | NIH-11295467 on NIH RePORTER |
What this research studies
Researchers will study cells and tumor models of H3K27M diffuse midline gliomas, a deadly childhood brain tumor, to see how diet-derived lipids influence which cell types the tumor cells become. They will focus on omega‑3 polyunsaturated fatty acids (n3‑PUFAs) and how these fats change chromatin marks that control gene activity and cell differentiation. Lab experiments will combine molecular assays (including chromatin and gene‑accessibility methods) with functional tests of tumor cell growth and lineage behavior. The goal is to link a specific dietary component to epigenetic changes that could reduce tumor aggressiveness and point toward new treatment strategies.
Who could benefit from this research
Good fit: Children with H3K27M diffuse midline gliomas or families willing to contribute tumor tissue, clinical data, or participate in related biospecimen efforts would be the most relevant participants.
Not a fit: Patients whose tumors do not carry the H3K27M oncohistone or those with unrelated neurological conditions are unlikely to receive direct benefit from this work.
Why it matters
Potential benefit: If successful, this could reveal a new, biologically informed way to push tumor cells toward less aggressive states and identify dietary or drug approaches that slow tumor growth.
How similar studies have performed: Preliminary lab work by the team and other preclinical studies suggest omega‑3 fats can promote differentiation in these tumor cells, but clinical testing of this approach is very limited.
Where this research is happening
Boston, United States
- Dana-Farber Cancer Inst — Boston, United States (Active)
Researchers
- Principal investigator: Danial, Nika N — Dana-Farber Cancer Inst
- Study coordinator: Danial, Nika N
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.